175 related articles for article (PubMed ID: 21719392)
1. Treatment of HIV-related primary central nervous system lymphoma with AZT high dose, HAART, interleukin-2 and foscarnet in three patients.
Marretta L; Stocker H; Drauz D; Mueller M; Masuhr A; Dieckmann S; Wong V; Koch A; Grueneisen A; Arastéh K; Weiss R
Eur J Med Res; 2011 May; 16(5):197-205. PubMed ID: 21719392
[TBL] [Abstract][Full Text] [Related]
2. Treatment of AIDS-related primary central nervous system lymphoma with zidovudine, ganciclovir, and interleukin 2.
Raez L; Cabral L; Cai JP; Landy H; Sfakianakis G; Byrne GE; Hurley J; Scerpella E; Jayaweera D; Harrington WJ
AIDS Res Hum Retroviruses; 1999 May; 15(8):713-9. PubMed ID: 10357467
[TBL] [Abstract][Full Text] [Related]
3. Antiviral and immunomodulatory treatment for AIDS-related primary central nervous system lymphoma: AIDS Malignancies Consortium pilot study 019.
Aboulafia DM; Ratner L; Miles SA; Harrington WJ;
Clin Lymphoma Myeloma; 2006 Mar; 6(5):399-402. PubMed ID: 16640817
[TBL] [Abstract][Full Text] [Related]
4. Highly active antiretroviral therapy as the sole treatment for AIDS-related primary central nervous system lymphoma: a case report with implications for treatment.
Aboulafia DM; Puswella AL
AIDS Patient Care STDS; 2007 Dec; 21(12):900-7. PubMed ID: 18154487
[TBL] [Abstract][Full Text] [Related]
5. Interleukin-2, ganciclovir, and high-dose zidovudine for the treatment of AIDS-associated primary central nervous system lymphoma.
Aboulafia DM
Clin Infect Dis; 2002 Jun; 34(12):1660-2. PubMed ID: 12032910
[No Abstract] [Full Text] [Related]
6. Experimental treatment of Epstein-Barr virus-associated primary central nervous system lymphoma.
Roychowdhury S; Peng R; Baiocchi RA; Bhatt D; Vourganti S; Grecula J; Gupta N; Eisenbeis CF; Nuovo GJ; Yang W; Schmalbrock P; Ferketich A; Moeschberger M; Porcu P; Barth RF; Caligiuri MA
Cancer Res; 2003 Mar; 63(5):965-71. PubMed ID: 12615710
[TBL] [Abstract][Full Text] [Related]
7. Long-term remission of AIDS-related primary central nervous system lymphoma in a patient under antiretroviral therapy: a case report and review of the literature.
Gijs PJ; Clerc O
AIDS Res Ther; 2021 Oct; 18(1):76. PubMed ID: 34666791
[TBL] [Abstract][Full Text] [Related]
8. Survival is prolonged by highly active antiretroviral therapy in AIDS patients with primary central nervous system lymphoma.
Skiest DJ; Crosby C
AIDS; 2003 Aug; 17(12):1787-93. PubMed ID: 12891064
[TBL] [Abstract][Full Text] [Related]
9. Whole brain radiation alone produces favourable outcomes for AIDS-related primary central nervous system lymphoma in the HAART era.
Nagai H; Odawara T; Ajisawa A; Tanuma J; Hagiwara S; Watanabe T; Uehira T; Uchiumi H; Yotsumoto M; Miyakawa T; Watanabe A; Kambe T; Konishi M; Saito S; Takahama S; Tateyama M; Okada S
Eur J Haematol; 2010 Jun; 84(6):499-505. PubMed ID: 20132301
[TBL] [Abstract][Full Text] [Related]
10. Survival of AIDS patients with primary central nervous system lymphoma is dramatically improved by HAART-induced immune recovery.
Hoffmann C; Tabrizian S; Wolf E; Eggers C; Stoehr A; Plettenberg A; Buhk T; Stellbrink HJ; Horst HA; Jäger H; Rosenkranz T
AIDS; 2001 Nov; 15(16):2119-27. PubMed ID: 11684931
[TBL] [Abstract][Full Text] [Related]
11. Zidovudine-based lytic-inducing chemotherapy for Epstein-Barr virus-related lymphomas.
Bayraktar UD; Diaz LA; Ashlock B; Toomey N; Cabral L; Bayraktar S; Pereira D; Dittmer DP; Ramos JC
Leuk Lymphoma; 2014 Apr; 55(4):786-94. PubMed ID: 23837493
[TBL] [Abstract][Full Text] [Related]
12. Human immunodeficiency virus-related primary central nervous system lymphoma: factors influencing survival in 111 patients.
Newell ME; Hoy JF; Cooper SG; DeGraaff B; Grulich AE; Bryant M; Millar JL; Brew BJ; Quinn DI
Cancer; 2004 Jun; 100(12):2627-36. PubMed ID: 15197806
[TBL] [Abstract][Full Text] [Related]
13. AIDS malignancies in the era of highly active antiretroviral therapy.
Gates AE; Kaplan LD
Oncology (Williston Park); 2002 May; 16(5):657-65; discussion 665, 668-70. PubMed ID: 12108891
[TBL] [Abstract][Full Text] [Related]
14. Changing pattern of primary cerebral lymphoma in the highly active antiretroviral therapy era.
Cingolani A; Fratino L; Scoppettuolo G; Antinori A
J Neurovirol; 2005; 11 Suppl 3():38-44. PubMed ID: 16540454
[TBL] [Abstract][Full Text] [Related]
15. Primary CNS lymphoma in HIV infection.
Brandsma D; Bromberg JEC
Handb Clin Neurol; 2018; 152():177-186. PubMed ID: 29604975
[TBL] [Abstract][Full Text] [Related]
16. Ganciclovir is associated with low or undetectable Epstein-Barr virus DNA load in cerebrospinal fluid of patients with HIV-related primary central nervous system lymphoma.
Bossolasco S; Falk KI; Ponzoni M; Ceserani N; Crippa F; Lazzarin A; Linde A; Cinque P
Clin Infect Dis; 2006 Feb; 42(4):e21-5. PubMed ID: 16421782
[TBL] [Abstract][Full Text] [Related]
17. Toxicology and Carcinogenesis Studies of Mixtures of 3'-Azido-3'-Deoxythymidine (AZT), Lamivudine (3TC), and Nevirapine (NVP) (CAS Nos. 30516-87-1, 134678-17-4, 129618-40-2) in Genetically Modified C3B6.129F1-Trp53(tm1Brd) N12 Haploinsufficient Mice (in utero and postnatal gavage studies).
National Toxicology Program
Natl Toxicol Program Genet Modif Model Rep; 2013 Oct; (16):1-236. PubMed ID: 24503698
[TBL] [Abstract][Full Text] [Related]
18. Long-term survival in AIDS-related primary central nervous system lymphoma.
Gupta NK; Nolan A; Omuro A; Reid EG; Wang CC; Mannis G; Jaglal M; Chavez JC; Rubinstein PG; Griffin A; Abrams DI; Hwang J; Kaplan LD; Luce JA; Volberding P; Treseler PA; Rubenstein JL
Neuro Oncol; 2017 Jan; 19(1):99-108. PubMed ID: 27576871
[TBL] [Abstract][Full Text] [Related]
19. Induction and maintenance therapy of cytomegalovirus central nervous system infection in HIV-infected patients.
Anduze-Faris BM; Fillet AM; Gozlan J; Lancar R; Boukli N; Gasnault J; Caumes E; Livartowsky J; Matheron S; Leport C; Salmon D; Costagliola D; Katlama C
AIDS; 2000 Mar; 14(5):517-24. PubMed ID: 10780714
[TBL] [Abstract][Full Text] [Related]
20. The management of primary central nervous system lymphoma related to AIDS in the HAART era.
González-Aguilar A; Soto-Hernández JL
Curr Opin Oncol; 2011 Nov; 23(6):648-53. PubMed ID: 21946245
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
